Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Samoa

  • What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of lymphatic filariasis (LF) has been reduced so that triple drug therapy with ivermectin, diethylcarbamazine, and albendazoe (IDA) can be stopped with little risk of resurgence of transmission?
  • To develop an M&E strategy that enables Samoa’s LF elimination program to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission
  • What is the effectiveness of appropriately dosed IDA in clearing Mf from Mf positive people who (i) reported taking IDA in August 2018, and (ii) did not report recently taking IDA?

 

Sites

Implementation partner(s): MOH - Samoa
WHO Region: WPRO

Notes

This is a multi-part study. The xenomonitoring has been completed and the human sampling is presently ongoing.

Email primary contact

Please log in or register